(Press-News.org) (ORLANDO, Dec. 6, 2025) Treatment with intravenous (IV) iron significantly improved survival and increased hemoglobin levels in patients with iron-deficiency anemia who were hospitalized for an acute bacterial infection, according to an analysis of data from more than 85,000 patients.
“Our data show that it is safe to give IV iron to patients who have both iron-deficiency anemia and an acute bacterial infection, and that, compared with untreated patients, those treated with IV iron have better overall survival and higher hemoglobin levels,” said lead author Haris Sohail, MD, a fellow in hematology-oncology at Charleston Area Medical Center in West Virginia.
IV iron is a standard treatment for severe iron-deficiency anemia, but its use in patients with both iron-deficiency anemia and an acute bacterial infection is controversial, Dr. Sohail said. Studies have shown that in laboratory experiments, certain bacteria can multiply when iron is added, he said. Although this effect has not been confirmed in human studies, he said, treatment guidelines have long recommended against giving IV iron to patients with active bacterial infections due to concern that the treatment could worsen the infection.
In this study, Dr. Sohail and his colleagues searched a large database of de-identified data from patients treated at medical centers across the United States for patients aged 18 and over with iron-deficiency anemia who were hospitalized with an acute bacterial infection between 2000 and 2024.
They collected data for over 85,000 patients with the five most common acute bacterial infections treated in U.S. hospitals – over 27,000 with pneumonia, over 23,000 with urinary tract infections, over 15,000 with methicillin-resistant staphylococcus aureus (MRSA), over 13,000 with cellulitis (a skin infection), and over 7,000 with colitis (inflammation of the colon) – as well as 143 patients with bacterial meningitis (inflammation of the membranes covering the brain and spinal cord).
The researchers then compared outcomes for patients who received IV iron treatment and those who did not. They looked at how many patients in each group died within 14 or 90 days, how long they spent in the hospital, and how much their hemoglobin levels increased at 60 to 90 days after IV iron treatment compared with the levels before treatment.
For every infection except meningitis, results showed that patients treated with IV iron were statistically significantly less likely to die within 14 or 90 days and had larger increases in hemoglobin levels than patients who did not receive IV iron. In patients with meningitis, IV iron did not improve survival, but did not worsen outcomes.
“The survival benefit of IV iron was seen across different types of infections, with the biggest improvements seen in patients with pneumonia, MRSA bacteria in the blood, and colitis,” Dr. Sohail said. While patients who received IV iron stayed slightly longer in the hospital, the difference was small – only about four to six hours – and not considered clinically meaningful, he said.
The small number of patients with bacterial meningitis likely explains why the findings for that infection were not statistically significant, Dr. Sohail said. He added that because the study reviewed the records of patients treated in the past, it can show only an association between IV iron and patient outcomes but cannot prove causation. Additional study limitations, he said, are that the database the researchers used did not provide detailed information about specific bacteria or iron doses, and the findings mainly apply to hospitalized patients with both iron-deficiency anemia and an active bacterial infection.
“Our findings support consideration of the use of IV iron as a safe additional therapy for patients who are hospitalized with both iron-deficiency anemia and an acute bacterial infection,” he said, adding that a next step would be to confirm these findings in a randomized controlled trial.
Haris Sohail, MD, of Charleston Area Medical Center, will present this study on Sunday, December 7, 2025, at 3:25 p.m. Eastern time during the plenary scientific session in West Hall D2 of the Orange County Convention Center.
###
The American Society of Hematology (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. Join the #Fight4Hematology by visiting hematology.org/fight4hematology.
The Blood journals (https://ashpublications.org/journals) are the premier source for basic, translational, and clinical hematologic research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide.
END
IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection
2025-12-06
ELSE PRESS RELEASES FROM THIS DATE:
Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients
2025-12-06
(ORLANDO, Dec. 6, 2025) Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health. Among patients with a mutation in their cancer cells that is generally associated with more favorable outcomes from AML treatment, survival for Black patients was ...
Emergency departments fall short on delivering timely treatment for sickle cell pain
2025-12-06
(ORLANDO, Dec. 6, 2025) A new study finds that only one in three patients visiting emergency departments (EDs) for severe pain associated with sickle cell disease received appropriate opioid-based pain-relieving medications within the first hour as recommended by the American Society of Hematology (ASH) and National Heart, Lung, and Blood Institute (NHLBI).
Based on data from several hundred medical centers across the United States, the research represents the first large, national study to assess guideline adherence across diverse EDs. It shows substantially ...
Study shows no clear evidence of harm from hydroxyurea use during pregnancy
2025-12-06
(ORLANDO, Dec. 6, 2025) Taking the sickle cell drug hydroxyurea during or shortly before pregnancy does not appear to cause specific issues in newborns, according to the first prospective study of pregnancies involving hydroxyurea exposure.
Since there may yet be undocumented effects, the authors still recommend discontinuing the drug before pregnancy, if possible. However, the findings offer reassurance that hydroxyurea exposure may not cause harm when unplanned pregnancies occur or when the drug is the only or best option ...
Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease
2025-12-06
(ORLANDO, Dec. 6, 2025) Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after their procedure, according to a new study. The study included over 1,000 patients, representing the largest and most comprehensive analysis of long-term transplant outcomes to date in people living with sickle cell disease.
“A majority of patients in this cohort are alive; the transplant worked so they no longer show symptoms of their sickle cell disease, and most have had no late effects post-transplant,” said lead study author Elizabeth Stenger, ...
Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia
2025-12-06
(ORLANDO, Dec. 6, 2025) The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers prepare to meet growing demand for gene therapies in the coming years.
“Gene therapy requires system-level coordination and close collaboration across patients, treatment centers, payers, and manufacturers,” said study author Joanne Lager, MD, chief medical officer at Genetix Biotherapeutics Inc. “The demand for these one-time durable gene ...
Early results suggest exa-cel gene therapy works well in children
2025-12-06
(ORLANDO, Dec. 6, 2025) Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12. Researchers say the therapy’s potential to offer a cure at an early age – before organ damage accumulates – could make exa-cel even more beneficial in children than adults.
“All younger patients with sufficient follow-up met the primary endpoint of being transfusion independent in those with beta thalassemia and free of vaso-occlusive crises for those with sickle cell disease,” said ...
NTIDE: Disability employment holds steady after data hiatus
2025-12-05
East Hanover, NJ – December 5, 2025 – The December 2025 National Trends in Disability Employment (nTIDE) report shows that employment outcomes for working-aged people with disabilities remain near historic highs, despite broader economic uncertainty. nTIDE reporting was on hiatus while the federal government shutdown delayed the release of employment data, which only recently became available.
Although employment and labor force participation edged down slightly in September, both measures continue to outperform year-to-year trends for workers without disabilities. Overall, the findings point to sustained labor market engagement among people with disabilities, ...
Social lives of viruses affect antiviral resistance
2025-12-05
Interactions among viruses can help them succeed inside their hosts or impart vulnerabilities that make them easier to treat. Scientists are learning the ways viruses mingle inside the cells they infect, as well as the consequences of their socializing.
Ph.D. student Alexander J. Robertson in the Molecular & Cellular Biology program at the University of Washington is among those scientists.
“I study the evolution of antimicrobial resistance through mechanisms which require interaction between microbes,” he explained.
This week he is the lead author of a paper in Nature Ecology & Evolution on that topic.
Polioviruses ...
Dose of psilocybin, dash of rabies point to treatment for depression
2025-12-05
ITHACA, N.Y. – An international collaboration led by Cornell University researchers used a combination of psilocybin and the rabies virus to map how – and where – the psychedelic compound rewires the connections in the brain.
Specifically, they showed psilocybin weakens the cortico-cortical feedback loops that can lock people into negative thinking. Psilocybin also strengthens pathways to subcortical regions that turn sensory perceptions into action, essentially enhancing sensory-motor responses.
The ...
Helping health care providers navigate social, political, and legal barriers to patient care
2025-12-05
In November, The Lancet, one of the world’s most esteemed medical journals, launched a new monthly series of case studies that goes beyond clinical diagnoses to illuminate the social and cultural forces that contribute to each patient’s condition.
Clinical case studies have long been a fixture in medical journals and are a primary way doctors and other health professionals continue learning after their initial training. Typically, case studies are short summaries of a patient’s predicament alongside a clinician’s assessment, diagnosis, ...